General synthesis of silica-based yolk/shell hybrid nanomaterials and in vivo tumor vasculature targeting
),
Weibo Cai1,2,3,5(
)
Download citation
496
Views
11
Downloads
27
Crossref
N/A
WoS
25
Scopus
2
CSCD
Multifunctional yolk/shell-structured hybrid nanomaterials have attracted increasing interest as theranostic nanoplatforms for cancer imaging and therapy. However, because of the lack of suitable surface engineering and tumor targeting strategies, previous research has focused mainly on nanostructure design and synthesis with few successful examples showing active tumor targeting after systemic administration. In this study, we report the general synthetic strategy of chelator-free zirconium-89 (89Zr)-radiolabeled, TRC105 antibody-conjugated, silica-based yolk/shell hybrid nanoparticles for in vivo tumor vasculature targeting. Three types of inorganic nanoparticles with varying morphologies and sizes were selected as the internal cores, which were encapsulated into single hollow mesoporous silica nanoshells to form the yolk/shell-structured hybrid nanoparticles. As a proof-of-concept, we demonstrated successful surface functionalization of the nanoparticles with polyethylene glycol, TRC105 antibody (specific for CD105/endoglin), and 89Zr (a positron-emitting radioisotope), and enhanced in vivo tumor vasculature-targeted positron emission tomography imaging in 4T1 murine breast tumor-bearing mice. This strategy could be applied to the synthesis of other types of yolk/shell theranostic nanoparticles for tumor-targeted imaging and drug delivery.
menu
General synthesis of silica-based yolk/shell hybrid nanomaterials and in vivo tumor vasculature targeting
), Weibo Cai1,2,3,5(
)
Abstract
Multifunctional yolk/shell-structured hybrid nanomaterials have attracted increasing interest as theranostic nanoplatforms for cancer imaging and therapy. However, because of the lack of suitable surface engineering and tumor targeting strategies, previous research has focused mainly on nanostructure design and synthesis with few successful examples showing active tumor targeting after systemic administration. In this study, we report the general synthetic strategy of chelator-free zirconium-89 (89Zr)-radiolabeled, TRC105 antibody-conjugated, silica-based yolk/shell hybrid nanoparticles for in vivo tumor vasculature targeting. Three types of inorganic nanoparticles with varying morphologies and sizes were selected as the internal cores, which were encapsulated into single hollow mesoporous silica nanoshells to form the yolk/shell-structured hybrid nanoparticles. As a proof-of-concept, we demonstrated successful surface functionalization of the nanoparticles with polyethylene glycol, TRC105 antibody (specific for CD105/endoglin), and 89Zr (a positron-emitting radioisotope), and enhanced in vivo tumor vasculature-targeted positron emission tomography imaging in 4T1 murine breast tumor-bearing mice. This strategy could be applied to the synthesis of other types of yolk/shell theranostic nanoparticles for tumor-targeted imaging and drug delivery.
References(71)
Ledford, H. Bankruptcy filing worries developers of nanoparticle cancer drugs. Nature 2016, 533, 304-305.
Shi, J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20-37.
Hare, J. I.; Lammers, T.; Ashford, M. B.; Puri, S.; Storm, G.; Barry, S. T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017, 108, 25-38.
Davis, M. E.; Chen, Z.; Shin, D. M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7, 771-782.
Chen, H. M.; Zhang, W. Z.; Zhu, G. Z.; Xie, J.; Chen, X. Y. Rethinking cancer nanotheranostics. Nat. Rev. Mater. 2017, 2, 17024.
Bradbury, M. S.; Pauliah, M.; Zanzonico, P.; Wiesner, U.; Patel, S. Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016, 8, 535-553.
Croissant, J. G.; Fatieiev, Y.; Khashab, N. M. Degradability and clearance of silicon, organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. Adv. Mater. 2017, 29, 1604634.
Purbia, R.; Paria, S. Yolk/shell nanoparticles: Classifications, synthesis, properties, and applications. Nanoscale 2015, 7, 19789-19873.
Piao, Y. Z.; Burns, A.; Kim, J.; Wiesner, U.; Hyeon, T. Designed fabrication of silica-based nanostructured particle systems for nanomedicine applications. Adv. Funct. Mater. 2008, 18, 3745-3758.
Benezra, M.; Penate-Medina, O.; Zanzonico, P. B.; Schaer, D.; Ow, H.; Burns, A.; DeStanchina, E.; Longo, V.; Herz, E.; Iyer, S. et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 2011, 121, 2768-2780.
Phillips, E.; Penate-Medina, O.; Zanzonico, P. B.; Carvajal, R. D.; Mohan, P.; Ye, Y. P.; Humm, J.; Gönen, M.; Kalaigian, H.; Schöder, H. et al. Clinical translation of an ultrasmall inorganic optical-pet imaging nanoparticle probe. Sci. Transl. Med. 2014, 6, 260ra149.
Chen, F.; Ma, K.; Benezra, M.; Zhang, L.; Cheal, S. M.; Phillips, E.; Yoo, B.; Pauliah, M.; Overholtzer, M.; Zanzonico, P. et al. Cancer-targeting ultrasmall silica nanoparticles for clinical translation: Physicochemical structure and biological property correlations. Chem. Mater. 2017, 29, 8766-8779.
Chen, F.; Ma, K.; Zhang, L.; Madajewski, B.; Zanzonico, P.; Sequeira, S.; Gonen, M.; Wiesner, U.; Bradbury, M. S. Target-or-clear zirconium-89 labeled silica nanoparticles for enhanced cancer-directed uptake in melanoma: A comparison of radiolabeling strategies. Chem. Mater. 2017, 29, 8269-8281.
Chen, F.; Zhang, X. L.; Ma, K.; Madajewski, B.; Benezra, M.; Zhang, L.; Phillips, E.; Turker, M. Z.; Gallazzi, F.; Penate-Medina, O. et al. Melanocortin-1 receptor-targeting ultrasmall silica nanoparticles for dual-modality human melanoma imaging. ACS Appl. Mater. Interfaces 2018, 10, 4379-4393.
Chen, F.; Goel, S.; Valdovinos, H. F.; Luo, H. M.; Hernandez, R.; Barnhart, T. E.; Cai, W. B. In vivo integrity and biological fate of chelator-free zirconium-89-labeled mesoporous silica nanoparticles. ACS Nano 2015, 9, 7950-7959.
Shaffer, T. M.; Wall, M. A.; Harmsen, S.; Longo, V. A.; Drain, C. M.; Kircher, M. F.; Grimm, J. Silica nanoparticles as substrates for chelator-free labeling of oxophilic radioisotopes. Nano Lett. 2015, 15, 864-868.
Shaffer, T. M.; Harmsen, S.; Khwaja, E.; Kircher, M. F.; Drain, C. M.; Grimm, J. Stable radiolabeling of sulfur-functionalized silica nanoparticles with copper-64. Nano Lett. 2016, 16, 5601-5604.
Ellison, P. A.; Chen, F.; Goel, S.; Barnhart, T. E.; Nickles, R. J.; DeJesus, O. T.; Cai, W. B. Intrinsic and stable conjugation of thiolated mesoporous silica nanoparticles with radioarsenic. ACS Appl. Mater. Interfaces 2017, 9, 6772-6781.
Chen, F.; Valdovinos, H. F.; Hernandez, R.; Goel, S.; Barnhart, T. E.; Cai, W. B. Intrinsic radiolabeling of titanium-45 using mesoporous silica nanoparticles. Acta Pharmacol. Sin. 2017, 38, 907-913.
Lee, J. E.; Lee, N.; Kim, T.; Kim, J.; Hyeon, T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc. Chem. Res. 2011, 44, 893-902.
Tang, F. Q.; Li, L. L.; Chen, D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv. Mater. 2012, 24, 1504-1534.
Chen, Y.; Chen, H. R.; Zeng, D. P.; Tian, Y. B.; Chen, F.; Feng, J. W.; Shi, J. L. Core/shell structured hollow mesoporous nanocapsules: A potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano 2010, 4, 6001-6013.
Chen, F.; Hong, H.; Zhang, Y.; Valdovinos, H. F.; Shi, S. X.; Kwon, G. S.; Theuer, C. P.; Barnhart, T. E.; Cai, W. B. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano 2013, 7, 9027-9039.
Chen, F.; Hong, H.; Goel, S.; Graves, S. A.; Orbay, H.; Ehlerding, E. B.; Shi, S. X.; Theuer, C. P.; Nickles, R. J.; Cai, W. B. In vivo tumor vasculature targeting of CuS@MSN based theranostic nanomedicine. ACS Nano 2015, 9, 3926-3934.
Chen, F.; Hong, H.; Shi, S. X.; Goel, S.; Valdovinos, H. F.; Hernandez, R.; Theuer, C. P.; Barnhart, T. E.; Cai, W. B. Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci. Rep. 2014, 4, 5080.
Shi, S. X.; Chen, F.; Cai, W. B. Biomedical applications of functionalized hollow mesoporous silica nanoparticles: Focusing on molecular imaging. Nanomedicine 2013, 8, 2027-2039.
Liu, J.; Qiao, S. Z.; Budi Hartono, S.; Lu, G. Q. Monodisperse yolk-shell nanoparticles with a hierarchical porous structure for delivery vehicles and nanoreactors. Angew. Chem., Int. Ed. 2010, 49, 4981-4985.
Chen, D.; Li, L. L.; Tang, F. Q.; Qi, S. Facile and scalable synthesis of tailored silica "nanorattle" structures. Adv. Mater. 2009, 21, 3804-3807.
Fan, W. P.; Shen, B.; Bu, W. B.; Chen, F.; Zhao, K. L.; Zhang, S. J.; Zhou, L. P.; Peng, W. J.; Xiao, Q. F.; Xing, H. Y. et al. Rattle-structured multifunctional nanotheranostics for synergetic chemo-/radiotherapy and simultaneous magnetic/luminescent dual-mode imaging. J. Am. Chem. Soc. 2013, 135, 6494-6503.
Liu, J. N.; Liu, Y.; Bu, W. B.; Bu, J. W.; Sun, Y.; Du, J. L.; Shi, J. L. Ultrasensitive nanosensors based on upconversion nanoparticles for selective hypoxia imaging in vivo upon near-infrared excitation. J. Am. Chem. Soc. 2014, 136, 9701-9709.
Liu, Y. Y.; Liu, Y.; Bu, W. B.; Xiao, Q. F.; Sun, Y.; Zhao, K. L.; Fan, W. P.; Liu, J. N.; Shi, J. L. Radiation-/hypoxia-induced solid tumor metastasis and regrowth inhibited by hypoxia-specific upconversion nanoradiosensitizer. Biomaterials 2015, 49, 1-8.
Chen, Y.; Chen, H. R.; Guo, L. M.; He, Q. J.; Chen, F.; Zhou, J.; Feng, J. W.; Shi, J. L. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano 2010, 4, 529-539.
Zhang, Q.; Zhang, T. R.; Ge, J. P.; Yin, Y. D. Permeable silica shell through surface-protected etching. Nano Lett. 2008, 8, 2867-2871.
Lin, L. S.; Song, J. B.; Yang, H. H.; Chen, X. Y. Yolk-shell nanostructures: Design, synthesis, and biomedical applications. Adv. Mater. 2018, 30, 1704639.
Liu, J.; Qiao, S. Z.; Chen, J. S.; Lou, X. W.; Xing, X. R.; Lu, G. Q. Yolk/shell nanoparticles: New platforms for nanoreactors, drug delivery and lithium-ion batteries. Chem. Commun. 2011, 47, 12578-12591.
Priebe, M.; Fromm, K. M. Nanorattles or yolk-shell nanoparticles--what are they, how are they made, and what are they good for? Chem. -Eur. J. 2015, 21, 3854-3874.
Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63, 136-151.
Chen, F.; Cai, W. B. Tumor vasculature targeting: A generally applicable approach for functionalized nanomaterials. Small 2014, 10, 1887-1893.
Seon, B. K.; Haba, A.; Matsuno, F.; Takahashi, N.; Tsujie, M.; She, X. W.; Harada, N.; Uneda, S.; Tsujie, T.; Toi, H. et al. Endoglin-targeted cancer therapy. Curr. Drug Deliv. 2011, 8, 135-143.
Rosen, L. S.; Hurwitz, H. I.; Wong, M. K.; Goldman, J.; Mendelson, D. S.; Figg, W. D.; Spencer, S.; Adams, B. J.; Alvarez, D.; Seon, B. K. et al. A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin. Cancer Res. 2012, 18, 4820-4829.
Hong, H.; Yang, K.; Zhang, Y.; Engle, J. W.; Feng, L. Z.; Yang, Y.; Nayak, T. R.; Goel, S.; Bean, J.; Theuer, C. P. et al. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 2012, 6, 2361-2370.
Chen, F.; Nayak, T. R.; Goel, S.; Valdovinos, H. F.; Hong, H.; Theuer, C. P.; Barnhart, T. E.; Cai, W. B. In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol. Pharmaceutics 2014, 11, 4007-4014.
Goel, S.; Chen, F.; Luan, S. J.; Valdovinos, H. F.; Shi, S. X.; Graves, S. A.; Ai, F. R.; Barnhart, T. E.; Theuer, C. P.; Cai, W. B. Engineering intrinsically zirconium-89 radiolabeled self-destructing mesoporous silica nanostructures for in vivo biodistribution and tumor targeting studies. Adv. Sci. 2016, 3, 1600122.
Zhou, J.; Liu, Z.; Li, F. Y. Upconversion nanophosphors for small-animal imaging. Chem. Soc. Rev. 2012, 41, 1323-1349.
Haase, M.; Schäfer, H. Upconverting nanoparticles. Angew. Chem., Int. Ed. 2011, 50, 5808-5829.
Ju, Q.; Tu, D. T.; Liu, Y. S.; Li, R. F.; Zhu, H. M.; Chen, J. C.; Chen, Z.; Huang, M. D.; Chen, X. Y. Amine-functionalized lanthanide-doped KGdF4 nanocrystals as potential optical/magnetic multimodal bioprobes. J. Am. Chem. Soc. 2012, 134, 1323-1330.
Wu, S. W.; Han, G.; Milliron, D. J.; Aloni, S.; Altoe, V.; Talapin, D. V.; Cohen, B. E.; Schuck, P. J. Non-blinking and photostable upconverted luminescence from single lanthanide-doped nanocrystals. Proc. Natl. Acad. Sci. USA 2009, 106, 10917-10921.
Cheng, L.; Wang, C.; Liu, Z. Upconversion nanoparticles and their composite nanostructures for biomedical imaging and cancer therapy. Nanoscale 2013, 5, 23-37.
Park, Y. I.; Kim, J. H.; Lee, K. T.; Jeon, K. S.; Bin Na, H.; Yu, J. H.; Kim, H. M.; Lee, N.; Choi, S. H.; Baik, S. I. et al. Nonblinking and nonbleaching upconverting nanoparticles as an optical imaging nanoprobe and T1 magnetic resonance imaging contrast agent. Adv. Mater. 2009, 21, 4467-4471.
Chatterjee, D. K.; Rufaihah, A. J.; Zhang, Y. Upconversion fluorescence imaging of cells and small animals using lanthanide doped nanocrystals. Biomaterials 2008, 29, 937-943.
Nam, S. H.; Bae, Y. M.; Park, Y. I.; Kim, J. H.; Kim, H. M.; Choi, J. S.; Lee, K. T.; Hyeon, T.; Suh, Y. D. Long-term real-time tracking of lanthanide ion doped upconverting nanoparticles in living cells. Angew. Chem., Int. Ed. 2011, 50, 6093-6097.
Xiong, L. Q.; Chen, Z. G.; Tian, Q. W.; Cao, T. Y.; Xu, C. J.; Li, F. Y. High contrast upconversion luminescence targeted imaging in vivo using peptide-labeled nanophosphors. Anal. Chem. 2009, 81, 8687-8694.
Chen, F.; Bu, W. B.; Zhang, S. J.; Liu, J. N.; Fan, W. P.; Zhou, L. P.; Peng, W. J.; Shi, J. L. Gd3+-ion-doped upconversion nanoprobes: Relaxivity mechanism probing and sensitivity optimization. Adv. Funct. Mater. 2013, 23, 298-307.
Chen, F.; Bu, W. B.; Zhang, S. J.; Liu, X. H.; Liu, J. N.; Xing, H. Y.; Xiao, Q. F.; Zhou, L. P.; Peng, W. J.; Wang, L. Z. et al. Positive and negative lattice shielding effects co-existing in Gd (Ⅲ) ion doped bifunctional upconversion nanoprobes. Adv. Funct. Mater. 2011, 21, 4285-4294.
Chen, F.; Bu, W. B.; Chen, Y.; Fan, Y. C.; He, Q. J.; Zhu, M.; Liu, X. H.; Zhou, L. P.; Zhang, S. J.; Peng, W. J. et al. A sub-50-nm monosized superparamagnetic Fe3O4@SiO2 T2-weighted MRI contrast agent: Highly reproducible synthesis of uniform single-loaded core-shell nanostructures. Chem. -Asian J. 2009, 4, 1809-1816.
Taylor, K. M. L.; Kim, J. S.; Rieter, W. J.; An, H. Y.; Lin, W. L.; Lin, W. B. Mesoporous silica nanospheres as highly efficient MRI contrast agents. J. Am. Chem. Soc. 2008, 130, 2154-2155.
Fang, X. L.; Chen, C.; Liu, Z. H.; Liu, P. X.; Zheng, N. F. A cationic surfactant assisted selective etching strategy to hollow mesoporous silica spheres. Nanoscale 2011, 3, 1632-1639.
Chen, F.; Ellison, P. A.; Lewis, C. M.; Hong, H.; Zhang, Y.; Shi, S. X.; Hernandez, R.; Meyerand, M. E.; Barnhart, T. E.; Cai, W. B. Chelator-free synthesis of a dual-modality PET/MRI agent. Angew. Chem., Int. Ed. 2013, 52, 13319-13323.
Zhuravlev, L. T. The surface chemistry of amorphous silica. Zhuravlev model. Colloids Surf. A 2000, 173, 1-38.
Fonsatti, E.; Nicolay, H. J.; Altomonte, M.; Covre, A.; Maio, M. Targeting cancer vasculature via endoglin/CD105: A novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc. Res. 2010, 86, 12-19.
Tian, B.; Wang, Q. H.; Su, Q. Q.; Feng, W.; Li, F. Y. In vivo biodistribution and toxicity assessment of triplet-triplet annihilation-based upconversion nanocapsules. Biomaterials 2017, 112, 10-19.
Sun, Y.; Feng, W.; Yang, P. Y.; Huang, C. H.; Li, F. Y. The biosafety of lanthanide upconversion nanomaterials. Chem. Soc. Rev. 2015, 44, 1509-1525.
Feng, Q. Y.; Liu, Y. P.; Huang, J.; Chen, K.; Huang, J. X.; Xiao, K. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci. Rep. 2018, 8, 2082.
Singh, N.; Jenkins, G. J. S.; Asadi, R.; Doak, S. H. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 2010, 1, 5358.
Tsoi, K. M.; Dai, Q.; Alman, B. A.; Chan, W. C. W. Are quantum dots toxic? Exploring the discrepancy between cell culture and animal studies. Acc. Chem. Res. 2013, 46, 662-671.
Ye, L.; Yong, K. T.; Liu, L. W.; Roy, I.; Hu, R.; Zhu, J.; Cai, H. X.; Law, W. C.; Liu, J. W.; Wang, K. et al. A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. Nat. Nanotechnol. 2012, 7, 453-458.
Zhang, Y.; Hong, H.; Severin, G. W.; Engle, J. W.; Yang, Y.; Goel, S.; Nathanson, A. J.; Liu, G.; Nickles, R. J.; Leigh, B. R. et al. ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Am. J. Transl. Res. 2012, 4, 333-346.
Zhang, Y.; Hong, H.; Orbay, H.; Valdovinos, H. F.; Nayak, T. R.; Theuer, C. P.; Barnhart, T. E.; Cai, W. B. PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 759-767.
Zhang, Y.; Hong, H.; Engle, J. W.; Yang, Y.; Barnhart, T. E.; Cai, W. Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am. J. Nucl. Med. Mol. Imaging 2012, 2, 1-13.
Shi, S. X.; Yang, K.; Hong, H.; Valdovinos, H. F.; Nayak, T. R.; Zhang, Y.; Theuer, C. P.; Barnhart, T. E.; Liu, Z.; Cai, W. B. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials 2013, 34, 3002-3009.
Hong, H.; Zhang, Y.; Severin, G. W.; Yang, Y.; Engle, J. W.; Niu, G.; Nickles, R. J.; Chen, X. Y.; Leigh, B. R.; Barnhart, T. E. et al. Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol. Pharmaceutics 2012, 9, 2339-2349.
Publication history
Copyright
Acknowledgements
This work is supported, in part, by the University of Wisconsin-Madison, the National Institutes of Health (P30CA014520 and NIBIB/NCI 1R01CA169365), the National Natural Science Foundation of China (No. 81630049), and the American Cancer Society (No. 125246-RSG-13-099-01-CCE).
FEEDBACK 
TOP